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The Second-Class Disease: Pediatric Cancer
“T
ommy” was a fit and happy boy who loved baseball and dino-
saurs. At the age of six, he began feeling tired all the time and 
developed a persistent cough that just would not quit. His pedia-
trician, labeling Tommy’s symptoms “allergy-like” and diagnosing 
him with a nasal drip, assured his family that he would get better soon. 
Unfortunately, he didn’t. Unlike other boys his age, between Cub Scout 
meetings and Little League games, for nearly one year of his short life he 
also unsuccessfully traversed the world of medical specialists, with expert 
after expert unable to identify why Tommy was sick. Eventually, with a 
worsening cough and the appearance of stomach pains and uncontrolled, 
erratic blinking, Tommy was referred to an otolaryngologist who then sug-
gested a consultation with an allergy specialist. With eosinophil counts in 
the hundreds of thousands, he was next referred to a hematologist, who 
finally discovered a 13-centimeter abdominal tumor. The diagnosis of stage 
IV Hodgkin’s lymphoma was finally made.
Pediatric malignancy is a far-reach-
ing problem. Nearly 11,000 children 
between the ages of 1 and 15 are 
diagnosed with cancer yearly (What 
is childhood cancer? 2009). More 
than a third of all boys and girls 
under the age of 20 will develop can-
cer, and over the past three decades 
incidence rates have slowly been ris-
ing (Ries et al. 1999).
Pediatric malignancy is also a devas-
tating diagnosis. For this age group, 
it is the leading cause of death from 
disease (What is childhood cancer? 
2009). Indeed, despite great advances 
in the medical management of pedi-
atric cancers, the five-year mortality 
rate is 20% (What is childhood can-
cer? 2009). For those who live past 
childhood, 30 years after diagnosis 
the cumulative incidence of chronic 
health conditions is nearly 73.4%, 
with a 42.4% incidence of death or 
severe, disabling, or life-threatening 
conditions (Oeffinger et al. 2006). 
Often, because these diseases affect 
multiple systems (Morris-Jones and 
Craft 1990), the child is relegated 
to a life of perpetual medical treat-
ment. Subsequently, the physical, 
social, and psychological effects on 
an entire family are massive (Cohen 
1999).
Despite its extensive reach and the 
reported poor outcomes, pediatric 
malignancy is severely underfunded. 
The National Cancer Institute (NCI), 
a branch of the National Institutes 
of Health (NIH) and the federal gov-
ernment’s principal cancer research 
and development agency (NIH 2010), 
had 2006 and 2007 budgets of $4.75 
and $4.79 billion, respectively (NIH 
2009a). Strikingly, its investment in 
pediatric cancer research was only 
$179.6 million in 2006, and this fig-
ure decreased to $172.7 million in 
2007 (NIH 2008). Additionally, con-
sidering that in 2003 its pediatric can-
cer research allocation was $152.8 
million, after adjusting for inflation 
using the Consumer Price Index, we 
realize that from 2003 to 2007 there 
was a mere $726,633 increase in 
pediatric funding, in contrast to a 
$40 million increase in the total NCI 
budget. The medical profession’s 
frustration about underfunded pedi-
atric cancer research is captured in 
the words of Gregory Reaman, M.D., 
chair of the Children’s Oncology 
Group: “Each day that pediatric can-
cer research goes under-funded, the 
road to discovering new treatments 
and cures become[s] longer, and 
more children are put at risk” (Hope 
Street kids join CureSearch 2005). In 
the case of Tommy and many like 
him, this lack of funding manifests 
itself in two perceptible forms: poor 
early detection, and a dearth of safe 
and effective treatment options.
One reason for the delay in Tommy’s 
diagnosis may be the typically 
asymptomatic initial clinical presen-
tation of Hodgkin’s lymphoma. Due 
to the indolent nature of the disease 
course, persistent painless supracla-
vicular or cervical lymphadenopathy 
is the most common symptom. In 
some cases of pediatric malignancy, 
because children commonly undergo 
cervical lymph node enlargement 
due to normal reactive processes, 
it is only the presence of supracla-
vicular nodes—rather than cervi-
cal nodes—that is indicative of the 
presence of the disease. In cases of 
intrathoracic Hodgkin’s lymphoma, 
associated findings include cough, 
dyspnea, chest pain, and superior 
vena cava syndrome. Axillary and 
inguinal lymphadenopathies are 
uncommon, and infradiaphragmatic 
nodal involvement is found in fewer 
than 5 percent of cases. In addition 
to lymphadenopathy, due to an 
increase in the number of stimu-
lating cytokines, lymphocytosis is 
present in some patients (Weinstein 
et al. 2007). Constitutional B symp-
toms such as fever, night sweats, and 
weight loss manifest in approxi-
mately 28.4% of patients. Tommy’s 
initial presentation of persistent 
flulike symptoms, which failed to 
resolve for more than a year, is con-
sistent with a more common and less 
dramatic presentation of Hodgkin’s 
lymphoma; this may also be why 
Tommy and his family were forced 
to spend nearly a year seeking guid-
ance from medical specialists who 
didn’t have definitive answers.
Unfortunately, even after his diag-
nosis, Tommy’s tribulations due to 
the inadequate medical manage-
ment of Hodgkin’s lymphoma were 
not yet over. Development of new 
therapies for childhood cancers has 
been lagging. From 1948 to 2003, 
the FDA approved 120 new cancer 
therapies for adults. Of those, dur-
ing the same time span, only 15 
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gained approval for pediatric use 
(Hirschfeld et al. 2003; DHHS 2003a). 
Inadequate funding of pediatric 
cancer research and development 
can be traced to a number of fac-
tors. Self-advocacy is not possible 
for children, and—as is evident in 
the decreasing federal funding for 
all pediatric cancers, which is now 
less than 3.59% of the $4.8 billion 
NCI budget—without political clout, 
pediatric cancers are not prioritized 
on Capitol Hill when new budgets 
are drawn up. Children’s cancers are 
also widely non-environmental and 
are not lifestyle-related, compared 
to those of adults (DHHS 2003b), and 
there are significantly more cases of 
adult cancer than there are of chil-
dren’s cancer (Alunedin et al. 2009). 
Accordingly, it is understandable 
that more funding is allocated for 
adult cancers, but should it be at the 
cost of a defenseless population?
Current treatment for Hodgkin’s 
lymphoma consists of variable-
length cycles of chemotherapy plus 
low-dose, involved field radiation 
(15-25 gy). Modern antiemetics have 
allowed for easier administration 
of the chemotherapy and radia-
tion therapy, but deleterious effects 
remain. The most common dose-
limiting factor in treatment is myelo-
suppression, which, although it 
can be ameliorated with the use of 
granulocyte colony–stimulating fac-
tors, still poses a significant risk. Also, 
the use of various vinca alkaloid 
compounds during treatment may 
be the cause of peripheral neuropa-
thies. Patients taking bleomycin may 
undergo relatively severe pulmonary 
toxicity, and patients taking doxoru-
bicin have been known (although 
rarely) to suffer from acute cardiac 
toxicity. With patients who have 
cervical involvement, side effects 
such as alopecia, dysphagia, xerosto-
mia, and taste alteration may result 
from the local effects of radiation 
therapy. A handful of patients may 
even experience a rare, transient 
myelopathy known as Lhermitte’s 
syndrome, in which an electric shock 
radiates down the patient’s back 
during neck flexion. Additionally, 
although certain treatments have 
achieved five-year survival rates that 
have approached 90%, this has not 
been without consequences (Fermé 
et al. 2007). The use of radiation 
therapy has increased the long-term 
risks of other malignancies for these 
patients, and the morbidity of mod-
ern chemotherapeutic drugs still 
carries significant weight. Future 
advancements in the treatment of 
Hodgkin’s lymphoma and other 
similar diseases lie in a better under-
standing of the cellular pathways 
that first lead to aberrant prolifera-
tion. With this knowledge, research-
ers will potentially be able to limit 
toxicity while providing effective 
treatment.
For Tommy, the next 14 years of his 
life after diagnosis kept him and 
his family on an emotional and 
physical roller coaster. Tommy was 
on various novel combinations of 
chemotherapeutic drugs that were 
often considered investigational, 
and underwent three bone-marrow 
transplants. Often at the expense of 
their own personal aspirations, his 
family tirelessly fought to ensure not 
only that Tommy received the best 
available medical care, but that he 
always be surrounded by a positive 
and enriching environment. When 
Tommy was ten, his doctors told the 
family he only had six months left to 
live, and that there was nothing else 
they could do. Refusing to accept 
this answer, the family inquired if 
other facilities could do any better, 
only to be told, “Alas, we all follow 
the same protocols.” After calls to 
hundreds of institutions across the 
country, Tommy’s mother stumbled 
upon a renowned facility where the 
doctors not only had access to new 
investigational drugs they believed 
would benefit Tommy, but to the 
family’s excitement also declared, 
“We can help him.” They were right, 
and in combination with the latest 
treatments available, Tommy lived 
another ten full and loving years.
One limitation in treatment options, 
the dearth of safe and effective 
chemotherapeutic drugs, is possibly 
the result of an average $800 mil-
lion cost of bringing one drug to 
market (DiMasi et al. 2003), which 
simply makes pediatric cancers not 
lucrative for the pharmaceutical 
industry. This is evident in that, on 
average, only one in five thousand 
novel compounds receives FDA 
approval (PhRMA 2004). This non-
existent financial incentive, and the 
commensurate lack of funding, add 
to the difficulties that normally face 
drug development such as sparse 
preclinical models (DHHS 2003a), the 
lag time between adult and pediat-
ric clinical trials for the same drug 
(DHHS 2003a), and the often inade-
quate sample size (Assent Task Force 
2010). Unfortunately, not every fam-
ily is as fortunate as Tommy’s. And 
not every family refuses to accept 
the status quo and realizes that 
there are more options out there.
However, despite this bleak real-
ity, there are some nonprofits that 
are working tirelessly to close the 
disparity in pediatric malignancy 
research funding. Organizations 
such as the Sean Hanna Foundation, 
Alex’s Lemonade Stand, and the 
Pediatric Cancer Foundation have 
taken up the challenge to provide 
for research leading to novel thera-
pies, early detection, and personal-
ized patient care. Ultimately, though, 
change must come from Capitol Hill.
In what had initially seemed a break-
through moment in the funding war, 
on December 16, 2009, President 
Obama signed H.R. 3288, effectively 
increasing the NCI’s 2010 budget by 
2.7%, to $5,103,388,000. Regrettably, 
pediatric malignancies continued to 
remain underfunded (NIH 2009b). 
According to Dr. Reaman, there will 
be consequences. “It’s very frustrat-
ing. It’s very disappointing. I think 
it will cost lives. And I think that is 
what people on Capitol Hill who 
make decisions about the federal 
budget need to understand. This 
will cost lives” (Budget cuts may hurt 
children with cancer 2007).
In 2007, at the age of 20, Tommy suc-
cumbed to graft-versus-host disease 
soon after his third bone marrow 
transplant, but he died disease-free. 
His passing was an indescribable loss 
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to those close to him, but his life—
like the example of sacrificial love 
embodied by his family—is a stark 
reminder of our duty to enact neces-
sary reform and unrelentingly advo-
cate for all our patients, especially 
those who are most dependent on 
us.
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